Clinical Trial Co.,Ltd
Company Overview
General Information
Corporate Philosophy
History
Access
CEO's Message
Introduction
Our role in clinical trials
Clinical Trial Services
Clinical Trial Events
Media Related Services
Press Room
2014年
2019
2014
2013
2012
2010
2009
Recruitment
Contact Us
日本語
Press Room
/ 2019
2019
2019/05/20
Based on the management and utilization of information by the University of Tokyo, 3H Holdings, and patients, we launched a new program to promote patient-centered drug development [Release by Group Company](In Japanese)
2019/07/01
Utilizing KOTAI Biotechnology x 3H Holdings “Rare Disease Research and Development Program Based on Patients” and calling for patient participation in “Study on specific immune status of autoimmune diseases”. [Group company release](In Japanese)
2019/08/20
We have completed the first “Rare Disease Research and Development Program Based on Patient-Centered Principles” to Connect Rare and Intractable Patients with Researchers. The three-month schedule has been significantly reduced to one month. Patient participation in "Study on specific immune status of autoimmune disease" [Group Company Press Release](In Japanese)
Press Room
2019
2014
2013
2012
2010
2009
2008